Blog - Sedgwick
Skip to content
Latest Coronavirus updates from Sedgwick Back to business solutions

Posts related to ‘FDA’

Search
Filter
View
Blog
May 07, 2020
Dr. Teresa Bartlett, Senior Medical Officer, Sedgwick and Max Koonce, Chief Claims Officer, Sedgwick
Virtual Wellness ZENter: Medical marijuana, hazy health and cloudy compliance

Has it ever been more important to be mindful, stay present and set a clear path for health and wellness than it is right now? For this year’s RIMS 2020 conference, Sedgwick had planned to invite attendees to join us in the annual Wellness ZENter, a …

May 07, 2020 by Dr. Teresa Bartlett, Senior Medical Officer, Sedgwick and Max Koonce, Chief Claims Officer, Sedgwick
Blog
March 27, 2020
Professional Liability Team, Sedgwick
Are you prepared? Healthcare and liability concerns during the coronavirus outbreak

As a claims organization, it’s up to us to keep our clients and their customers informed on current issues and deliver peace of mind. The healthcare, product liability and life sciences space is constantly evolving, but we’re keeping an eye on the fo…

March 27, 2020 by Professional Liability Team, Sedgwick
Blog
October 05, 2018
Dr. Reema Hammoud
Director Clinical Pharmacy
DEA and FDA clear Epidiolex: Where do we go from here?

On September 27, 2018, the Drug Enforcement Agency (DEA) made a remarkable move. The agency placed a cannabidiol (CBD) containing product, Epidiolex, into Schedule V (classified as having low potential for abuse) so that it could be manufactured in t…

October 05, 2018 by Dr. Reema Hammoud, Director Clinical Pharmacy
Blog
February 02, 2017
In the weeds on marijuana and workers’ compensation

It’s a topic that gets much buzz – how will the cloud of legislation surrounding recreational and medical marijuana use impact businesses, specifically when it comes to compensability for workers’ compensation? I am sure you have all caught up on n…

February 02, 2017
Blog
April 04, 2016
Dr. Teresa Bartlett
Senior Medical Officer
Dangerous prescribing practices and at-risk patients – a look at best practices

It was my privilege to present along with Dr. Paul Peak of Sedgwick at the 2016 National RX Drug and Heroin Summit in Atlanta, Georgia to discuss dangerous prescribing practices and at-risk patients. The conference was highlighted by a public ap…

April 04, 2016 by Dr. Teresa Bartlett, Senior Medical Officer
Blog
January 15, 2016
Dr. Reema Hammoud
Director Clinical Pharmacy
Misuse of antipsychotics in workers’ compensation patients

Antipsychotics are medications used for the treatment of acute and chronic psychosis and other psychotic conditions. Besides their defined indication by the Food and Drug Administration, antipsychotics are often used and misused for off-label condi…

January 15, 2016 by Dr. Reema Hammoud, Director Clinical Pharmacy
Blog
October 13, 2015
April Clemens, Business Relationship Manager-PL
Transparency and pharmaceutical drug samples

Kathy Shostek, Vice President Healthcare Risk Management contributed a recent post about the management of drug samples in physician offices. The blog outlined the need for strategies for documentation and management of drug samples for reducing ri…

October 13, 2015 by April Clemens, Business Relationship Manager-PL
Blog
August 19, 2015
Dr. Paul Peak
Assistant Vice President Clinical Pharmacy
3D drug printers: Better care vs. Safety risks

Last week, the Food and Drug Administration (FDA) made an extremely unique drug approval that was the first of its kind. In fact, it was one of the most revolutionary drug-related approvals seen in years. The FDA approved the first 3D printed drug,…

August 19, 2015 by Dr. Paul Peak, Assistant Vice President Clinical Pharmacy
Blog
June 12, 2015
Blunt talk on federal marijuana action

Over the last several years, I’ve been talking about how medical marijuana will ultimately become an issue in workers’ compensation and, with several cases we’ve seen across the country, this has become a reality. In each of my pieces, there is alway…

June 12, 2015
Blog
February 26, 2015
Dr. Paul Peak
Assistant Vice President Clinical Pharmacy
Zohydro ER gets FDA approval…but will it really help prevent abuse?

On January 30, 2015 the Food and Drug Administration (FDA) approved a reformulated version of Zohydro ER (a long-acting, single-entity hydrocodone product) that is designed to possess abuse-deterrent properties. When the FDA originally approve…

February 26, 2015 by Dr. Paul Peak, Assistant Vice President Clinical Pharmacy
Blog
June 12, 2014
Brenda Corey
SVP Compliance & Regulatory Affairs
How will medical technology and privacy coexist?

A commercial ran recently where a man getting in his car sees a sticky note on his window. When he reads the note it says, "you are going to have a heart attack today." The voiceover states, "It's too bad we aren't notified when we are going to have …

June 12, 2014 by Brenda Corey, SVP Compliance & Regulatory Affairs
End of results.
Loading...